Shandong Wohua Pharmaceutical Co Ltd - Class A

SZSE:002107 (China)   Class A
Â¥ 4.57 (+0.44%) May 27
57.13
P/B:
3.24
Market Cap:
Â¥ 2.64B ($ 364.24M)
Enterprise V:
Â¥ 2.17B ($ 299.62M)
Volume:
3.61M
Avg Vol (2M):
6.54M
Volume:
3.61M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Shandong Wohua Pharmaceutical Co Ltd ( SZSE:002107 ) from 2007 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shandong Wohua Pharmaceutical stock (SZSE:002107) PE ratio as of May 27 2024 is 57.13. More Details

Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) PE Ratio (TTM) Chart

To

Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) PE Ratio (TTM) Historical Data

Total 1191
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Shandong Wohua Pharmaceutical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-27 57.1 2024-03-18 49.0
2024-05-24 56.9 2024-03-15 47.5
2024-05-23 60.1 2024-03-14 47.1
2024-05-22 60.9 2024-03-13 47.4
2024-05-21 61.4 2024-03-12 48.7
2024-05-20 61.9 2024-03-11 46.2
2024-05-17 61.5 2024-03-08 45.4
2024-05-16 61.1 2024-03-07 44.8
2024-05-15 61.3 2024-03-06 45.4
2024-05-14 62.0 2024-03-05 44.8
2024-05-13 61.1 2024-03-04 46.3
2024-05-10 62.4 2024-03-01 46.0
2024-05-09 63.5 2024-02-29 46.0
2024-05-08 62.6 2024-02-28 43.9
2024-05-07 62.8 2024-02-27 48.6
2024-05-06 62.3 2024-02-26 48.6
2024-04-30 60.3 2024-02-23 46.8
2024-04-29 59.5 2024-02-22 44.4
2024-04-26 56.5 2024-02-21 42.6
2024-04-25 55.9 2024-02-20 41.4
2024-04-24 55.3 2024-02-19 40.5
2024-04-23 54.4 2024-02-08 37.4
2024-04-22 52.6 2024-02-07 35.5
2024-04-19 52.5 2024-02-06 39.4
2024-04-18 53.4 2024-02-05 41.0
2024-04-17 53.5 2024-02-02 45.5
2024-04-16 48.6 2024-02-01 48.4
2024-04-15 54.0 2024-01-31 49.6
2024-04-12 58.4 2024-01-30 52.5
2024-04-11 59.0 2024-01-29 54.8
2024-04-10 59.5 2024-01-26 56.7
2024-04-09 61.5 2024-01-25 56.4
2024-04-08 59.8 2024-01-24 53.3
2024-04-03 62.1 2024-01-23 52.4
2024-04-02 62.3 2024-01-22 53.4
2024-04-01 62.3 2024-01-19 57.0
2024-03-29 60.6 2024-01-18 57.6
2024-03-28 60.6 2024-01-17 59.2
2024-03-27 48.0 2024-01-16 60.1
2024-03-26 48.3 2024-01-15 60.8
2024-03-25 48.7 2024-01-12 60.3
2024-03-22 49.3 2024-01-11 61.3
2024-03-21 50.1 2024-01-10 61.2
2024-03-20 49.9 2024-01-09 61.8
2024-03-19 49.3 2024-01-08 61.3

Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.